Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry.

Haralabos P KalofonosEmmanouil V DermitzakisGeorgia XiromerisiouDimitrios RikosDimitrios RallisPanagiotis SoldatosPantelis LitsardopoulosAnna P AndreouMichail Vikelis

Published in: Expert review of neurotherapeutics (2024)

Fremanezumab can be considered a very effective treatment option for preventing migraines in difficult-to-treat women, aged 18-70 years, regardless of their menopausal status.

Keyphrases

randomized controlled trial
polycystic ovary syndrome
systematic review
postmenopausal women
pregnancy outcomes
combination therapy
metabolic syndrome
skeletal muscle
insulin resistance